The Competition Commission of Pakistan (CCP) has approved the acquisition of trademarks related to the pharmaceutical product Claforan by M/s. Hoechst Pakistan Limited from M/s. Sanofi Aventis Deutschland GMBH under the Trademark Assignment Agreement. Hoechst Pakistan Limited is a publicly listed company in Pakistan with specialization in manufacturing, selling, and trading pharmaceutical products. Meanwhile, Sanofi Aventis Deutschland GMBH is a limited liability company based in Germany and focuses on manufacturing and distributing pharmaceuticals. Through this transaction, Sanofi Aventis Deutschland GMBH, a prominent European pharmaceutical manufacturer, istransferring the trademarks, positioning Hoechst as a significant player in Pakistan’s pharmaceutical industry. In its assessment, the CCP identified the relevant market as ‘Systemic Antibiotics’ and classified the transaction as a horizontal merger. Moreover, Hoechst Pakistan’s market share will remain unchanged, as it has already been producing Claforan under a license from Sanofi Aventis, thus avoiding any shift in market balance while enhancing its strategic footprint. The CCP has determined that this acquisition will not result in market dominance and has therefore authorized the transaction under Section 31(1)(d)(i) of the Act, ensuring competitive balance within Pakistan’s systemic antibiotics market.
The Competition Commission of Pakistan (CCP) has approved the acquisition of trademarks related to the pharmaceutical product Claforan by M/s. Hoechst Pakistan Limited from M/s. Sanofi Aventis Deutschland GMBH under the Trademark Assignment Agreement.
Hoechst Pakistan Limited is a publicly listed company in Pakistan with specialization in manufacturing, selling, and trading pharmaceutical products. Meanwhile, Sanofi Aventis Deutschland GMBH is a limited liability company based in Germany and focuses on manufacturing and distributing pharmaceuticals.
Through this transaction, Sanofi Aventis Deutschland GMBH, a prominent European pharmaceutical manufacturer, istransferring the trademarks, positioning Hoechst as a significant player in Pakistan’s pharmaceutical industry.
In its assessment, the CCP identified the relevant market as ‘Systemic Antibiotics’ and classified the transaction as a horizontal merger. Moreover, Hoechst Pakistan’s market share will remain unchanged, as it has already been producing Claforan under a license from Sanofi Aventis, thus avoiding any shift in market balance while enhancing its strategic footprint.
The CCP has determined that this acquisition will not result in market dominance and has therefore authorized the transaction under Section 31(1)(d)(i) of the Act, ensuring competitive balance within Pakistan’s systemic antibiotics market.
© CCP 2024, Competition Commission of Pakistan ©All rights reserved
